01998nas a2200277 4500000000100000008004100001260001300042653001000055653003000065653001700095653001100112653001100123653002300134653001200157653000900169653001600178653001000194653001500204100001200219700001600231245008200247300001100329490000800340520135800348022001401706 2004 d c2004 May10aAdult10aDrug Therapy, Combination10aEye diseases10aFemale10aHumans10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aNepal10aPrevalence1 aNepal B1 aShrestha UD00aOcular findings in leprosy patients in Nepal in the era of multidrug therapy. a888-920 v1373 a

PURPOSE: Detailed ophthalmic evaluation was performed to determine the prevalence of ocular complications among leprosy patients on multidrug therapy and those released from multidrug treatment.

DESIGN: Observational case series.

METHODS: Leprosy patients at Tribhuvan University Teaching Hospital from April 1, 2001, through September 30, 2002, underwent detailed ophthalmic evaluation including slit-lamp biomicroscopy, dilated funduscopy, and applanation tonometry.

RESULTS: We evaluated 58 leprosy patients. A majority (72%) was receiving treatment for multibacillary leprosy; 14% belonged to posttreatment multibacillary and paucibacillary groups. Ocular involvement was found in 57% of patients. In the multibacillary group, 55% had ocular involvement, which was more than double that found in the paucibacillary group (25%), although this finding was not statistically significant (P =.187). Among patients with ocular complications, 48% had visual disability and another 45% had threatened vision; 9% met World Health Organization guidelines for blindness. Uveitis and its complications were the predominant causes of visual disability (88%).

CONCLUSION: Ocular complications and visual disability are high among leprosy patients in Nepal even after completing multidrug therapy.

 a0002-9394